Mirae Asset Global Investments Co. Ltd. Buys 541 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 21.3% during the third quarter, Holdings Channel.com reports. The fund owned 3,078 shares of the company’s stock after acquiring an additional 541 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Syndax Pharmaceuticals were worth $58,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Values First Advisors Inc. bought a new position in Syndax Pharmaceuticals during the 3rd quarter worth $30,000. Assenagon Asset Management S.A. increased its stake in shares of Syndax Pharmaceuticals by 8.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 466,028 shares of the company’s stock valued at $8,971,000 after purchasing an additional 37,079 shares during the last quarter. Inspire Investing LLC increased its stake in shares of Syndax Pharmaceuticals by 23.2% in the 3rd quarter. Inspire Investing LLC now owns 21,308 shares of the company’s stock valued at $410,000 after purchasing an additional 4,018 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter valued at $234,000. Finally, Quarry LP increased its stake in shares of Syndax Pharmaceuticals by 75.0% in the 2nd quarter. Quarry LP now owns 6,125 shares of the company’s stock valued at $126,000 after purchasing an additional 2,625 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on SNDX shares. UBS Group started coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 price target on the stock. Stifel Nicolaus lifted their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Citigroup lifted their price target on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Bank of America raised their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Finally, JPMorgan Chase & Co. cut their price objective on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.90.

Syndax Pharmaceuticals Trading Up 4.0 %

Shares of SNDX opened at $19.69 on Wednesday. The company has a market capitalization of $1.68 billion, a PE ratio of -5.83 and a beta of 0.92. Syndax Pharmaceuticals, Inc. has a 12 month low of $13.14 and a 12 month high of $25.34. The stock’s 50-day moving average price is $19.05 and its two-hundred day moving average price is $20.31.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).